Cue Biopharma, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Cue Biopharma, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $3.35M.
- Cue Biopharma, Inc. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $5.78M.
- Cue Biopharma, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $5.59M.
- Cue Biopharma, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $2.02M, a 66.30% decline year-over-year.
- Cue Biopharma, Inc. stock issued during period, value, new issues for fiscal 2023 was $13.39M.
- Cue Biopharma, Inc. stock issued during period, value, new issues for fiscal 2021 was $17.38M, a 69.33% decline from fiscal 2020.
- Cue Biopharma, Inc. stock issued during period, value, new issues for fiscal 2020 was $56.68M, a 15.68% increase from fiscal 2019.
- Cue Biopharma, Inc. stock issued during period, value, new issues for fiscal 2019 was $49.00M, a 1075.22% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-03-31 | $3.35M 10-Q · filed 2024-05-09 | $16.74M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $5.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.39M 10-K · filed 2025-03-31 |
| 2023-09-30 | $5.59M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $2.02M 10-Q · filed 2023-08-08 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $23.63M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $5.98M 10-Q · filed 2023-08-08 | $23.63M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $10.62M 10-Q · filed 2023-05-09 | $28.00M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $7.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $17.38M 10-K · filed 2023-03-21 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | |
| 2021-06-30 | $10.36M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $236.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $56.68M 10-K · filed 2022-03-16 |
| 2020-09-30 | $14.33M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $42.35M 10-Q · filed 2020-08-07 | |
| 2019-12-31 | $33.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $49.00M 10-K · filed 2021-03-09 |
| 2019-09-30 | $11.94M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $3.71M 10-Q · filed 2019-08-08 | |
| 2018-12-31 | $4.17M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |